Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report

Joseph Kattan 1Clarisse Kattan 1Fadi Farhat 2Tarek Assi 2 3


1Hematology-Oncology Department, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut.

2Hematology-Oncology Department, Hammoud Hospital UMC, Saida.

3Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

PMID: 31490286

DOI: 10.1097/CAD.0000000000000827


The advent of BRAF and MEK inhibitors changed the landscape of the management of BRAF mutated melanoma patients. In this article, we report the case of a 51-year-old man with BRAF mutated locally advanced cutaneous melanoma of the head who demonstrated a limited response to initial anti-BRAF monotherapy followed by extensive surgery. Anti-PD1 therapy failed to reverse the disease progression. However, subsequent double inhibition of the BRAF and MEK pathways induced a fast and remarkable tumour response.